Skip to main content
. 2023 Apr 4;18(4):e0273202. doi: 10.1371/journal.pone.0273202

Fig 2. Disease progression at day 14 from hospital admission.

Fig 2

Distribution of the WHO-CPS scores at day 28 of patients admitted for COVID-19 with baseline SuPAR ≥ 6 ng/mL and non-severe respiratory failure who received and did not receive anakinra (Control Group 1). Comparison is done by unadjusted ordinal regression analysis; the ORs of the 95% CIs are provided. COVID-19 = coronavirus disease 2019. SuPAR = soluble urokinase plasminogen activator receptor. OR = odds ratio.